Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Waters and Ireland's NIBRT Partner on Training and Research

Published: Thursday, September 27, 2012
Last Updated: Wednesday, September 26, 2012
Bookmark and Share
The partnership will increase large molecule characterization capacity and knowledge, helping to deliver new, more effective therapeutic options.

The Irish National Institute for Bioprocessing Research and Training (NIBRT) and Waters® Corporation have announced that they have formed a multi-level partnership designed to support advanced concepts and deliver the promise of more effective biotherapeutic innovations addressing the world's most challenging diseases through both training and research.

Waters and NIBRT have established the Complete Product and Processing Characterization Facility (CPPCF) for hands-on laboratory based scientific training and retraining of 'fit-for-purpose' biopharmaceutical analysis, including protein and peptide characterization.

The CPPCF's goal is to provide comprehensive training of industry and governmental technicians and scientists to help the burgeoning industry develop advanced biotherapeutic characterization.

The new facility will also educate scientists on existing and upcoming U.S. and European drug regulations.

Furthermore, the partnership establishes NIBRT as a Waters Center of Innovation in the area of glycobiology research.

Prof. Pauline Rudd, NIBRT's principal investigator, and her team will be working with Waters mass spectrometry based systems to take challenging glycan characterization to the next level.

By improving understanding of glycan chemical and molecular structure, scientists can better understand safety and efficacy profiles for a potential molecule, leading directly to novel biotherapeutic options.

Officiating the opening ceremonies for the two new laboratories, Mr. Sean Sherlock TD, Minister for Research and Innovation, Department of Jobs, Enterprise & Innovation commented, "The combination of Pauline Rudd's expertise in glycan analysis and Waters technology for analysis of complex biological samples provides a unique combination of capabilities that can help underpin Ireland's continued reputation as a centre of excellence for the very highest quality standards in biopharmaceutical manufacturing. I'm truly delighted to announce this collaboration as it will surely assist both NIBRT and Waters in further cementing their reputation as providers of choice for the biopharmaceutical industry and Ireland's reputation as a world leading location for biotech manufacturing."

Biopharmaceuticals are increasingly important to patients and drug manufacturers. By 2014, it is expected that 50% of the top 100 prescribed medications will be biopharmaceuticals, including four of the top five selling drugs.

Welcoming this partnership, NIBRT's Interim Director Prof Ian Marison commented, "Ireland is a leading location globally for the development and manufacture of complex biopharmaceutical drugs. This is due in large part to a sustained commitment to quality and compliance with the highest regulatory standards.

"NIBRT was created by the Irish government to underpin the biopharmaceutical industry. One key area that NIBRT will focus on is research into improved product analytics to assist the industry in maintaining exacting quality standards. A second key area is bioanalytical training in the most modern and advanced analytical methods.

"This is being achieved through a major partnership with Waters, who are world leaders in analytical equipment development. This partnership will enable NIBRT, with the help of Waters, to provide advanced solutions for the pharmaceutical industry, including protein characterization, N- and O- glycan analysis."

Waters is the leader in biopharmaceutical analytical technology, which is fundamental to the advancement of biopharmaceuticals.

The company offers a comprehensive technology solution that gives biopharmaceutical manufacturers the analytics they need from discovery to development to commercialization and everything in between.

"Through this lab and other collaborations, Waters will work with industry to improve the development of biopharmaceuticals and inform governments on the types of regulations that should be put in place," said Mike Harrington, Waters Vice President, European Operations.

Industry and government biopharmaceutical leaders in Europe and beyond applauded the Waters-NIBRT partnership.

Waters' effort with NIBRT is the latest demonstration of the company's commitment to creating partnerships that enable it to multiply its impact on critical public health issues, including food safety, safe drugs and clean water.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

R&D 100 Award Goes to Waters ionKey/MS System
Novel approach is enhancing the sensitivity of bioanalytical, biomarker validation, pharmacokinetic and food research LC/MS analyses.
Thursday, November 26, 2015
SIMM Honored by Waters Centers of Innovation Program
Research Center for traditional Chinese medicine modernization recognized for advancing quality control authentication and profiling methods.
Wednesday, October 28, 2015
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Wednesday, September 23, 2015
Waters Corporation Announces Christopher J. O'Connell as CEO
Chris joins Waters® from Medtronic plc.
Thursday, July 02, 2015
Waters Centers of Innovation Program Honors CSU Laboratory
Proteomics and metabolomics facility recognized for innovation in biological mass spectrometry.
Wednesday, October 29, 2014
Waters Q3 Revenues up 8 Percent
Company reports third quarter sales of $493 million, an increase of 8% versus sales of $457 million in the third quarter of 2013.
Tuesday, October 21, 2014
Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
New Solutions to Old Challenges
Waters Corporation introduces a new NuGenesis Lab Management System (LMS) that integrates sample management functions and business operations across the enterprise. Technology Networks' Editor Helen Gillespie interviewed Waters' Garrett Mullen for details.
Tuesday, July 01, 2014
Waters, Prosolia Exclusive Agreement for DESI Technology for Clinical MS Applications
Prosolia DESI Technology now available on SYNAPT G2 Si and Xevo G2-XS QTof mass spectrometers.
Monday, June 16, 2014
Waters, Omics LLC Partner to Advance Petroleum Sample Analysis
Collaboration Combines the Value of Ion Mobility Mass Spectrometry (IM-MS) and Accurate Mass Information with Petroleomics Data Processing.
Monday, June 16, 2014
Waters ACQUITY UPLC TQD System Receives Chinese FDA Approval
Chinese FDA approves ACQUITY UPLC TQD system for routine diagnostic applications and neonatal metabolites diseases screening.
Thursday, June 05, 2014
Waters ACQUITY QDa Detector Takes Pittcon Editors' Award
Product receives Editors' Silver award for the most innovative product introduced at Pittcon 2014.
Monday, March 10, 2014
Waters Report 8% Revenue Increase
Fourth quarter 2013 sales were $565 million, an increase of 8% compared to sales of $522 million in the fourth quarter of 2012.
Tuesday, January 28, 2014
Waters Teams With Biochemical Society on Proteomics Training Day and Symposium
The consecutive events will take place on March 24 - 27, 2014 in Chester, England.
Wednesday, November 27, 2013
Waters Acquires Nonlinear Dynamics
Nonlinear Dynamics is best known for their Progenesis software which offers researchers unique ways to analyze and visualize the raw proteomic data.
Thursday, August 08, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos